Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis. Read more about Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis.
A distinct innate lymphoid cell population regulates tumor-associated T cells. Read more about A distinct innate lymphoid cell population regulates tumor-associated T cells.
Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Read more about Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states.
Capturing the biology of disease severity in a PSC-based model of familial dysautonomia. Read more about Capturing the biology of disease severity in a PSC-based model of familial dysautonomia.
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Read more about PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Read more about A framework for understanding and targeting residual disease in oncogene-driven solid cancers.
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Read more about Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Read more about PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Read more about Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Read more about Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
